

☐

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

<div>1. Name and Address of Reporting Person*</div> <div><div>Gayko Urte</div><div>(Last)(First)(Middle)</div><div>C/O SUMMIT THERAPEUTICS INC. ONE BROADWAY, 14TH FLOOR</div><div>(Street)</div><div>CAMBRIDGEMA02142</div><div>(City)(State)(Zip)</div></div>	<div>2. Issuer Name and Ticker or Trading Symbol</div> <div>Summit Therapeutics Inc. [ SMMT ]</div> <div>3. Date of Earliest Transaction (Month/Day/Year)</div> <div>11/03/2021</div> <div>4. If Amendment, Date of Original Filed (Month/Day/Year)</div>	<div>5. Relationship of Reporting Person(s) to Issuer (Check all applicable)</div> <div><div>X</div>Director10% Owner</div> <div>Officer (give title below)Other (specify below)</div>
---	---	--

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$5.54	11/03/2021		A		200,000		(1)11/03/2031		Common Stock	200,000	(3)	200,000	D	
Stock Option (right to buy)	\$5.54	11/03/2021		A		4,041		(2)11/03/2031		Common Stock	4,041	(3)	204,041	D	

Explanation of Responses:

1. The option was granted on November 3, 2021. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on November 3, 2022.
2. The option was granted on November 3, 2021 and represents a pro rata amount of the annual 25,000 option board grant based approximately on the number of days this year the reporting person is anticipated to serve as a director. The shares underlying the option are scheduled to vest in full on December 31, 2021.
3. Not applicable.

/s/ Urte Gayko11/16/2021

\*\* Signature of Reporting PersonDate

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.